NewsBenzingaJP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145 JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145 Benzinga 2026.10.15 16:01 (GMT+0) Open on Benzinga Other news $1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today Lam Research Q1 2027 Earnings Call Transcript Texas Capital Bancshares Q3 2026 Earnings Call Transcript If You Invested $100 In Comfort Systems USA Stock 20 Years Ago, You Would Have This Much Today Tesla Executive Says Expect Around Q2 Next Year To Turn On Some Customer Cars To Be Part Of Robotaxi Fleet; Trying To To Get Cybercabs To Customers By The End Of This Year Pinnacle Finl Partners Affirms FY2026 Sales Guidance of $5.000B-$5.200B
Tesla Executive Says Expect Around Q2 Next Year To Turn On Some Customer Cars To Be Part Of Robotaxi Fleet; Trying To To Get Cybercabs To Customers By The End Of This Year
